The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Current challenges in treating advanced GIST beyond first-line therapy
Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland, highlights the ongoing challenges in managing advanced gastrointestinal stromal tumors (GIST), particularly after progression on first-line therapy with tyrosine kinase inhibitors (TKIs) such as imatinib. While treatments like sunitinib and regorafenib provide additional options in later lines, progression-free survival (PFS) remains limited in subsequent therapies. Current clinical trials are focusing on improving outcomes in the second line of therapy, as significant advancements beyond fourth-line treatment remain elusive. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
